Vanda Pharmaceuticals gets FDA orphan drug status for VPO-227 in cholera

TAGS

Vanda Pharmaceuticals has secured orphan drug designation for from the US Food and Drug Administration () for the treatment of .

According to the Nasdaq-listed biopharma company, cholera continues to be a significant public health challenge and recognized unmet medical need in spite of public health efforts over many years.

See also  Biocon expands generics portfolio with Tacrolimus launch in US

Commenting on VPO-227 FDA orphan drug designation, — Vanda Pharmaceuticals President, CEO, and Chairman of the Board, said: “This designation is an important milestone in the development of VPO-227 and highlights the need for potential new treatment options for patients who suffer from cholera and other conditions of water hyper-excretion.”

See also  REV Group to launch bullet-proof REV Guardian ambulance

VPO-227 is a small-molecule designed to block the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, said Vanda Pharmaceuticals.

CFTR is said to have a crucial role in intestinal fluid loss induced by cholera as it is affected by the cholera toxin.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This